Hydroxyurea for sickle cell disease
is a topic covered in the Evidence-Based Medicine Guidelines
To view the entire topic, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
"Hydroxyurea for Sickle Cell Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454434/all/Hydroxyurea_for_sickle_cell_disease.
Hydroxyurea for sickle cell disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/454434/all/Hydroxyurea_for_sickle_cell_disease. Accessed October 16, 2019.
Hydroxyurea for sickle cell disease. (2019). In Evidence-Based Medicine Guidelines. Available from https://evidence.unboundmedicine.com/evidence/view/EBMG/454434/all/Hydroxyurea_for_sickle_cell_disease
Hydroxyurea for Sickle Cell Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2019 October 16]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454434/all/Hydroxyurea_for_sickle_cell_disease.
TY - ELEC
T1 - Hydroxyurea for sickle cell disease
ID - 454434
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454434/all/Hydroxyurea_for_sickle_cell_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine